User login
Key clinical point: Eptinezumab (100 and 300 mg) was efficacious compared with placebo with an acceptable safety and tolerability profile in patients with episodic and chronic migraine and 2-4 previous unsuccessful preventive treatments.
Major finding: In 1-12 weeks, 100 and 300 mg eptinezumab vs placebo led to a significantly higher reduction in mean monthly migraine days (difference from placebo −2.7 and −3.2, respectively; both P < .0001) and higher odds of ≥75% migraine responder rates (odds ratio 9.2 and 11.4, respectively; both P < .0001), with comparable treatment-emergent adverse events.
Study details: Findings are from the phase 3b DELIVER trial including 892 patients with episodic and chronic migraine and 2-4 previous unsuccessful preventive treatments who were randomly assigned to receive eptinezumab (100 or 300 mg) or placebo.
Disclosures: This study was supported by H Lundbeck. Five authors reported being full-time employees or owning stock or stock options in H Lundbeck or its subsidiaries. Several authors reported ties with various sources and scientific journals.
Source: Ashina M et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): A multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022;21(7):597-607 (Jul 1). Doi: 10.1016/S1474-4422(22)00185-5
Key clinical point: Eptinezumab (100 and 300 mg) was efficacious compared with placebo with an acceptable safety and tolerability profile in patients with episodic and chronic migraine and 2-4 previous unsuccessful preventive treatments.
Major finding: In 1-12 weeks, 100 and 300 mg eptinezumab vs placebo led to a significantly higher reduction in mean monthly migraine days (difference from placebo −2.7 and −3.2, respectively; both P < .0001) and higher odds of ≥75% migraine responder rates (odds ratio 9.2 and 11.4, respectively; both P < .0001), with comparable treatment-emergent adverse events.
Study details: Findings are from the phase 3b DELIVER trial including 892 patients with episodic and chronic migraine and 2-4 previous unsuccessful preventive treatments who were randomly assigned to receive eptinezumab (100 or 300 mg) or placebo.
Disclosures: This study was supported by H Lundbeck. Five authors reported being full-time employees or owning stock or stock options in H Lundbeck or its subsidiaries. Several authors reported ties with various sources and scientific journals.
Source: Ashina M et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): A multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022;21(7):597-607 (Jul 1). Doi: 10.1016/S1474-4422(22)00185-5
Key clinical point: Eptinezumab (100 and 300 mg) was efficacious compared with placebo with an acceptable safety and tolerability profile in patients with episodic and chronic migraine and 2-4 previous unsuccessful preventive treatments.
Major finding: In 1-12 weeks, 100 and 300 mg eptinezumab vs placebo led to a significantly higher reduction in mean monthly migraine days (difference from placebo −2.7 and −3.2, respectively; both P < .0001) and higher odds of ≥75% migraine responder rates (odds ratio 9.2 and 11.4, respectively; both P < .0001), with comparable treatment-emergent adverse events.
Study details: Findings are from the phase 3b DELIVER trial including 892 patients with episodic and chronic migraine and 2-4 previous unsuccessful preventive treatments who were randomly assigned to receive eptinezumab (100 or 300 mg) or placebo.
Disclosures: This study was supported by H Lundbeck. Five authors reported being full-time employees or owning stock or stock options in H Lundbeck or its subsidiaries. Several authors reported ties with various sources and scientific journals.
Source: Ashina M et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): A multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022;21(7):597-607 (Jul 1). Doi: 10.1016/S1474-4422(22)00185-5